Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JIN 001

Next Previous
X
Search
Drug Profile

JIN 001

Alternative Names: JIN-001; MPT0B64; MPT0B640

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Joseah Biopharma
  • Developer J Ints Bio; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Antivirals; Aromatic hydrocarbons; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Glioblastoma; Ovarian cancer; Parkinson's disease
  • Discontinued COVID 2019 infections

Most Recent Events

  • 24 Oct 2024 Preclinical trials in Ovarian cancer in South Korea (unspecified route), prior to October 2024
  • 24 Oct 2024 Pharmacodynamics data from preclinical trial in Ovarian cancer released by J Ints Bio
  • 24 Oct 2024 J INTS BIO, in collaboration with MD Anderson Cancer Center, plans a clinical trial for Glioblastoma in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top